Kyverna Therapeutics Reported Clinical Trial Results
The company shared long-term data for its cell therapy candidate, miv-cel, in patients with stiff-person syndrome.
Updated on Sept. 24, 2026 in Biotech
Live Poll
Do you believe the clinical benefits of new cell therapies justify the risks for patients?
Kyverna Therapeutics released 12-month clinical results from its KYSA-8 trial showing significant mobility improvements for patients with stiff-person syndrome. Most participants maintained these benefits without the need for additional chronic immunotherapies.
Why it matters
These positive long-term outcomes provide key evidence for the potential of cell-based therapies in treating autoimmune diseases. The results support the company's ongoing strategy to advance miv-cel through the regulatory approval process.
The KYSA-8 study of 26 patients found 95% of those who showed initial improvement maintained clinical benefits at 12 months. Additionally, 92% of participants remained free from chronic immunotherapies following the treatment.
The players
Kyverna Therapeutics
This clinical-stage biopharmaceutical company focuses on developing cell therapies for patients suffering from autoimmune diseases.
The details
The KYSA-8 study demonstrated that 67% of participants who previously required walking assistance no longer needed aids after treatment. Separately, 86% of participants in the related KYSA-6 trial remained off immunosuppressive therapies after 24 weeks.
Timeline
June 2026 marked the data lock for the KYSA-6 trial follow-up.
July 2026 marked the data lock for the KYSA-8 trial follow-up.
The company plans to submit a Biologics License Application in Q4 2026.
Enrollment for the Phase 3 portion of the KYSA-6 study is expected to conclude in mid-2027.
The Tech Race
This development marks a shift toward utilizing advanced cell therapy platforms to address complex autoimmune conditions that historically relied on lifelong immunosuppression. Kyverna Therapeutics is positioning miv-cel as a potential new standard of care within this evolving biotech sector.
Patients with stiff-person syndrome may eventually gain access to a treatment that reduces dependence on chronic immunotherapies and improves daily mobility. Investors should note that the company share price stood at $7.81 following the recent disclosure.
The takeaway
These findings underscore the growing efficacy of targeted cell therapies in providing durable relief for patients with chronic autoimmune conditions. Future research will continue to assess whether these improvements can be sustained over even longer time horizons.
What happens next
Kyverna Therapeutics intends to complete its Biologics License Application submission in the fourth quarter of 2026 and expects to finish enrollment for the Phase 3 KYSA-6 study by mid-2027.
Further reading
Learn more about the latest developments in Biotech.
Live Poll
Do you believe the clinical benefits of new cell therapies justify the risks for patients?
